Alliance for Pandemic Preparedness

January 20, 2021

Neutralization of SARS-CoV-2 Lineage B.1.1.7 Pseudovirus by BNT162b2 Vaccine-Elicited Human Sera

Category:

Keywords (Tags): ,

[Pre-print, not peer-reviewed] A study comparing two SARS-CoV-2 non-replicating laboratory-produced pseudoviruses bearing either the spike proteins of the Wuhan reference strain or the B.1.1.7 variant strain concluded that it was unlikely that the new variant would escape immune effectors induced by the Pfizer/BioNTech vaccine (BNT162b2). No biologically significant difference in neutralization activity against the two pseudoviruses was observed among sera from 16 participants from the previously-reported German phase 1/2 trial.

Muik et al. (Jan 19, 2021). Neutralization of SARS-CoV-2 Lineage B.1.1.7 Pseudovirus by BNT162b2 Vaccine-Elicited Human Sera. BioRxiv. https://doi.org/10.1101/2021.01.18.426984